在CALGB 10403方案中整合贝林妥欧单抗巩固治疗用于可测量残留病阴性的成人B细胞前体急性淋巴细胞白血病
本研究描述将贝林妥欧单抗巩固治疗按本机构共识加入CALGB 10403方案的經驗,31例成人患者中位年龄31岁,中位随访13.7个月,中位总生存未达到,全级别细胞因子释放综合征发生率9.7%,治疗相关神经/精神不良事件发生率19.4%,无患者因毒性永久停用贝林妥欧单抗,作者认为该整合方案安全可行。
要点
- 31例成人患者中位随访13.7个月,中位总生存未达到,发生1例死亡和1例复发(3.2%)。
- 全级别细胞因子释放综合征发生率9.7%,治疗相关神经/精神不良事件发生率19.4%,无患者因毒性永久停用贝林妥欧单抗。
- 84.6%的患者能够接受超过一半的计划培门冬酶剂量。
核心结论
- 将贝林妥欧单抗巩固治疗整合入CALGB 10403方案在成人急性淋巴细胞白血病患者中安全且可行。
研究设计与样本
- 本研究描述按本机构共识将贝林妥欧单抗巩固治疗加入CALGB 10403方案的經驗,31例成人患者符合纳入标准。
主要发现
- 中位年龄31岁,大多数为男性(64.5%)和西班牙裔(83.9%),最常见的急性淋巴细胞白血病亚型为费城染色体样(45.2%)。
- 中位随访13.7个月,中位总生存未达到(95%置信区间未达到-未达到),发生1例异基因移植后死亡和1例复发(3.2%)。
- 全级别细胞因子释放综合征发生率为9.7%,治疗相关神经/精神不良事件发生率为19.4%,无患者因毒性永久停用贝林妥欧单抗。
- 84.6%的患者能够接受超过一半的计划培门冬酶剂量。
临床怎么用
- 作者认为,将贝林妥欧单抗巩固治疗整合入CALGB 10403方案在成人急性淋巴细胞白血病患者中安全且可行。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Blinatumomab consolidation was recently approved for patients with acute lymphoblastic leukaemia (ALL) who achieve measurable residual disease (MRD) negative remission based on the survival benefit yielded in the E1910 trial. The CALGB 10403 (C10403) is the most frequently used paediatric inspired regimen for young adults treated in the United States; however, data and guidance on how to best incorporate blinatumomab consolidation into the C10403 regimen are lacking. Here, we describe our experience of adding blinatumomab consolidation to the C10403 regimen per our institutional consensus. Thirty-one adult patients met inclusion criteria. The median age was 31 years and the majority were males (64.5%) and Hispanic (83.9%). The most common ALL subtype was Philadelphia-like (45.2%). The median follow-up was 13.7 months and the median overall survival was not reached (NR) (95% confidence interval [CI] NR-NR) with one death occurring post allogenic transplant and one relapse (3.2%). All-grade cytokine release syndrome and treatment-related neurological/psychiatric adverse event rates were 9.7% and 19.4%, respectively, and none of the patients permanently discontinued blinatumomab due to toxicity. The majority (84.6%) of patients were able to receive over half of their planned pegaspargase doses. The incorporation of blinatumomab consolidation to C10403 is safe and feasible in adults with ALL.
引用
- Tinajero J, Ngo D, Motta M, et al. The integration of blinatumomab consolidation in the CALGB 10403 regimen for adults with B-cell precursor acute lymphoblastic leukaemia in measurable residual disease-negative remission. Br J Haematol. 2025. PMID: 40492422. doi:10.1111/bjh.20200
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。